What is my company doing to help humanity in 2025?

We should all ask ourselves that same question, right now!!!

Well, wait. Do that - after you read :). But, definitely do it...you'll feel great about it.

In any event...here is my story...

Let's just say 2024 was a "fascinatingly interesting" chapter in my life, as I imagine it was in yours. To use colorful language, it was firetrucking crazy.

Well, it just got crazier!

I couldn't have told you 2 months ago...that this is how life would unfold.

But, here it is...

My generative AI consulting company is evolving in a way that is going to blend my life's passions! OMG! Wow! AMAZING!

It combines a) my study of neuropsychology - a life's passion for helping humanity b) using the most of my life's professional experience - which I have absolutely loved (data, artificial intelligence, and generative AI), and applying those two things for c) digital therapeutics for psychology, health, and wellness. This last part is something I've been looking into for 14 years!

This is insane!

Plus, my clients, partners, and investors are all touching this space! adambloom.me is blessed!

OMG! Let's do this 2025!

Here is the current state, at the moment of publishing this article

My professional practice has led me to a new way of thinking about life and business. This year, we've focused a lot on Gen AI - what a transition year it has been. I cannot even begin to explain the number of Gen AI tests I have run this year. Call centers are all over it. CMOs and CROs are about to get totally disrupted, and it isn't going to be pretty.

In any event, my closest business partner has had a parallel journey this year (my friend Thomas Schryver ) a long career focused on biotech, digital therapeutics, pharma, and healthcare in a private equity environment. So, we have had major overlap in life, business, and years of work that leads up to a wonderful moment!

So, here is what I am forming...what do you think so far?

Our technology drives human health improvements and massively reduces costs through stress-related biomarker data, artificial intelligence neural networks, & Generative AI. Most importantly, our ethos, which permeates every decision in our company, is to always put the human first.

Our mission is to be better than any other company on Earth at delivering the best health outcomes at the lowest costs, to ultimately help other humans. Our innovations are based on 14 years of scientific study of the hypothalamic-pituitary-adrenal (HPA) axis and its related neuropsychology.

For anyone that is interested in some of our research and would like to discuss opportunities, please reach out! Below is a short article - and outlines some of the scientific areas we are commercializing.

====

The Best Neuropsychology Innovations of 2024

By: adambloom.me 12-21-2024 <> 2024-12-21

This past year, I’ve been amazed by the transformative advances in neuropsychology. It is even more amazing how technology and data is entering digital therapeutics. From groundbreaking diagnostic sensor apps to digital therapies and new insights into the brain-behavior connection. It has just been another amazing year in this science!

While below list isn’t exhaustive, I’ve curated examples that stand out for their potential to reshape how we understand and treat the human mind.

TY!ab

1. Novel Biomarkers and Diagnostics

a. Blood-Based Biomarkers for Alzheimer’s Disease

• Recent progress in blood-based testing (e.g., measuring phosphorylated tau proteins) has improved early and less invasive detection of Alzheimer’s.
• These biomarkers can potentially transform clinical practice by allowing cost-effective, large-scale screening and monitoring of disease progression.

b. Advanced MRI and PET Techniques

• Developments in positron emission tomography (PET) tracers have enabled more specific imaging of pathological proteins (e.g., tau vs. amyloid), offering nuanced insights into neurodegenerative processes.
• Ultra-high-field MRI (7T and above) has improved structural resolution, helping researchers visualize smaller brain structures involved in cognition and behavior with greater clarity.

2. Brain Stimulation and Neuromodulation

a. Noninvasive Deep Brain Stimulation (DBS)

• Research efforts have been directed toward making DBS less invasive and more targeted, such as using focused ultrasound or novel electrode designs that selectively modulate deep subcortical areas.
• These developments hold promise for treatment-resistant depression, obsessive-compulsive disorder (OCD), and other neuropsychiatric conditions.

b. Refined TMS Protocols

• Transcranial magnetic stimulation (TMS) has undergone refinements for personalized neuromodulation, including individualized coil placement guided by neuroimaging.
• New TMS protocols, such as theta-burst stimulation (iTBS), require less time and show promising outcomes for both depression and cognitive enhancement.

3. Psychedelic-Assisted Therapies

• Continued clinical trials of psychedelic compounds (e.g., psilocybin, MDMA) have shown potential for treating treatment-resistant depression, PTSD, and addiction.
• Neuropsychology research has begun to map the acute and long-term brain changes accompanying these therapies, offering insights into mechanisms of emotional processing and neuroplasticity.

4. Digital Therapeutics and Virtual Reality (VR)

a. VR-Based Interventions for Phobias and PTSD

• Virtual reality exposure therapy (VRET) is becoming more accessible, with improved graphics and sensors enabling therapists to deliver controlled, customized environments.
• Studies show that VR-based interventions can effectively reduce anxiety and trauma-related symptoms, often complementing traditional therapy approaches.

b. Mobile Assessments and “Neuro Apps”

• Smartphone-based cognitive assessments and “digital phenotyping” platforms now gather moment-to-moment behavioral data.
• These tools allow clinicians and researchers to monitor changes in cognition and mood in real time, generating large datasets for personalized treatment strategies.

5. Artificial Intelligence and Cognitive Modeling

a. AI-Assisted Diagnostics

• Machine learning models are refining the ability to detect early signs of dementia, Parkinson’s disease, and other neurodegenerative disorders from MRI scans, EEG data, or even language samples.
• AI-driven analysis of EEG patterns has shown potential for identifying subtle cognitive deficits linked to ADHD, sleep disorders, and anxiety.

b. Computational Psychiatry and Cognitive Modeling

• Integrating computational models with neuroimaging is helping researchers understand how specific neural circuits drive decision-making and reward learning.
• These models can pinpoint dysfunction in conditions like schizophrenia or depression, potentially leading to more targeted interventions.

6. Advances in Gene Editing and Regenerative Approaches

• Although still largely in the research phase, CRISPR-based strategies targeting genetic mutations responsible for certain forms of familial dementia or ALS (amyotrophic lateral sclerosis) have shown promise.
• Stem cell therapies and organoid research continue to expand in scope, allowing scientists to study patient-specific cellular models of neurological disorders in vitro and test novel treatments more rapidly.

7. Expanded Understanding of the Gut-Brain Axis

• The relationship between gut microbiota and cognitive/affective functioning has garnered increasing interest.
• Interdisciplinary work in neuropsychology, immunology, and gastroenterology has revealed further links between microbiome composition and mental health conditions (e.g., anxiety, depression), potentially paving the way for microbiome-targeted therapies.

Looking Forward

The past year’s advances underscore a growing convergence of technologies—imaging, genomics, neuromodulation, digital tools, and AI—to form a more integrative approach in neuropsychology. Collaboration across fields such as psychiatry, neurology, computer science, and engineering continues to open new frontiers. In the coming years, we can expect further progress in:

• Precision medicine, with ever more personalized brain stimulation protocols and drug regimens.
• Translational research, bridging basic neuroscience discoveries to everyday clinical practice.
• Ethical frameworks, ensuring the responsible implementation of new techniques (e.g., gene editing, AI-driven analytics).

Taken together, these innovations bring us closer to a future where researchers and clinicians can intervene earlier and more precisely, improving cognitive and emotional health outcomes for individuals worldwide.